Breaks Categories: News

FridayMay 17, 2024 2:52 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of investigation are being explored in this study, including evaluating whether DehydraTECH-processed oral GLP-1 drugs are more effective than non-DehydraTECH-processed oral GLP-1 drugs in reaching brain tissue, improving weight loss and improving control of blood sugar. The study will also evaluate…

Continue Reading

TuesdayMay 14, 2024 4:42 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and business results for the third quarter of 2024, the period that ended March 31, 2024. Business highlights included the announcement of preclinical data supporting both the company’s INM-901 and INM-089 programs; the continued development of its ALZ program, with long-term behavioral and mechanism of action/receptor interaction studies underway; and the announcement of Dr. David G. Morgan, a leader in neurodegenerative disease, to the company’s scientific advisory board. The report also noted that BayMedica is operating…

Continue Reading

WednesdayMay 08, 2024 2:18 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

Continue Reading

MondayMay 06, 2024 3:08 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Continue Reading

WednesdayMay 01, 2024 3:53 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Responds to Announcement Rescheduling of Marijuana by DEA

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a holding company focused in the cannabis and agricultural technology sectors, released an official reaction to the “historic milestone” in the cannabis industry as the U.S. Drug Enforcement Administration (“DEA”) moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (“CSA:). The reclassification was fueled by a recommendation from the U.S. Department of Health and Human Services and represents a notable change in U.S. drug policy. According to the announcement from MedCana, cannabis has been unjustly categorized as a Schedule I substance alongside heroin and LSD for…

Continue Reading

WednesdayMay 01, 2024 2:19 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

Continue Reading

MondayApr 29, 2024 2:43 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) CEO Featured Guest in Most Recent Bell2Bell Podcast

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, is spotlighted in the latest episode of the Bell2Bell Podcast, released from IBN. During the interview, GTVH president and CEO Steffan Dalsgaard talks with Bell2Bell host Stuart Smith about the company and Destino Ranch, its flagship project designed to be a tourist attraction, large immersive art installation and music festival venue; the ranch will be located about an hour from Las Vegas. As part of the development, Golden Triangle Ventures has purchased 70 acres and acquired ABI Create, one of the largest event developers in the country. In addition, Dalsgaard noted…

Continue Reading

ThursdayApr 25, 2024 1:01 pm

CBDNewsBreaks – InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Subsidiary Establish Four-Pillar Business Model to Ensure Successful Development of Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment (or “Lavish”), have developed a comprehensive four-pillar business model. According to the announcement, the company intends for this key business component to be a critical component moving forward as Lavish Entertainment focuses on creating an industry-leading entertainment business. Specifically, the business model will be used as the company’s flagship project, Destino Ranch, is being developed. The new business model includes four essential key foundational elements: logistics, staffing, equipment and production. The company noted that these specific pillars were carefully identified and organized to complement…

Continue Reading

WednesdayApr 24, 2024 2:52 pm

CBDNewsBreaks – Software Effective Solutions Corp.’s (SFWJ) Eko2o S.A.S. Marks Significant Step in Strategy to Increase Global Footprint

Eko2o S.A.S., a pioneering force in agricultural technology and infrastructure and a majority-controlled subsidiary of Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), today announced its continued growth and expansion as a key infrastructure supplier for some of Colombia’s largest flower producers. In addition, the company announced it is enhancing its support and sales operations with international partnerships, notably with Danziger International, one of the flower industry’s most respected names. According to the announcement, the expanding partnership with Danziger International marks a significant step in Eko2o’s strategy to increase its global footprint and is expected to boost Eko2o’s visibility on the…

Continue Reading

TuesdayApr 16, 2024 3:42 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

Continue Reading